Arsenic trioxide (ATO), which is used to treat patients with acute promyelocytic leukemia (APL), binds to thiol groups in cysteine residues and induces degradation of proteins, such as promyelocytic leukemia protein (PML) and PML-retinoic acid receptor α (PML-RARα) fusion protein (85). The gene discussed is PML; the disease is acute promyelocytic leukemia.